Drug Trial Radar · NCT02974907
Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome : ARISE-2
Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
601
Actual
Start
Nov 2016
Primary completion
Sep 2017
Study completion Mar 2018
Sponsor
- Lead sponsor
- ReGenTree, LLCIndustry
- Sponsor type
- Industry
- First posted
- Nov 29, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study is to compare the safety and efficacy of RGN-259 Ophthalmic Solutions to placebo for the treatment of the signs and symptoms of dry eye.
Conditions
- Dry Eye Syndrome
Interventions
RGN-259Drug
A preservative-free, sterile eye drop solution containing Tβ4 for direct instillation into each eye, four times a day (QID) for 28 days
PlaceboDrug
It is composed of the same excipients as RGN-259 but does not contain Tβ4
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Ocular DiscomfortTime frame: Day 29
- Change in Fluorescein StainingTime frame: Day 29
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
Cornea & Cataract Consultants of Arizona
Phoenix, Arizona
Eye Research Foundation
Newport Beach, California
Vision Institute
Colorado Springs, Colorado
The Eye Care Group
Waterbury, Connecticut
Midwest Cornea Associates, LLC
Indianapolis, Indiana
Eye Care Institute
Louisville, Kentucky
Andover Eye Associates
Andover, Massachusetts
Total Eye Care, P.A.
Memphis, Tennessee
Nashville Vision Associates
Nashville, Tennessee
Eye Consultants of Texas
Grapevine, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.